Current role of pravastatin in the treatment of hyperlipidaemia

Česká verzia

Authors: L. Špinarová; J. Vítovec
Authors place of work: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in the journal: Kardiol Rev Int Med 2010, 12(3): 138-142

Summary

The authors review the use of statins in patients with hyperlipoproteinaemia focusing on pravastatin. They discuss indications, adverse effects and comparisons to other statins. In addition, examples of clinical use in primary and secondary prevention patients and after heart transplantation are provided.

Keywords:
hyperlipoproteinaemia – pravastatin – heart transplantation

Zdroje

1. Katznelson S, Wang XM, Chia D et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T-lymphocyte activity in vitro. J Heart Lung Transpl 1998; 17: 335–340.

2. Widimský J. Léčba dyslipidémií. Praha: Triton 2002.

3. Vítovec J, Špinar J a kol. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Praha: Grada 2004.

4. Češka R, Slíva J. Pravastatin a jeho místo v terapii dyslipidemií v roce 2010. Farmakoterapie 2009; 6: 603–607.

5. Bellosta S, Paolleti R, Corsiny A. Safety of Statins. Focus on Clinical Pharmakokinetics and Drug Interactions. Circulation 2004; 109: III50–III57.

6. Thompson PD, Clarkson P, Karas RH et al. Statin-associated myopathy. JAMA 2003; 289: 1681–1690.

7. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.

8. Ford I, Murray H, Packard CJ et al. Long-term follow-up of the West Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477–1486.

9. Pffeffer MA, Sacks FM, Moyé LA et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999; 33: 125–130.

10. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patiens with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

11. Pitt B, Mancini GB, Ellis SG et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis and clinical events. PLAC I investigation. J Am Coll Cardiol 1995; 26: 1133–1139.

12. Crouse JR 3rd, Byington RP, Bond MG et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995; 75: 455–459.

13. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–2540.

14. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623–1630.

15. Špinarová L, Toman J. Pharmacotherapy after heart transplatation. Cor Vasa 2000; 42: 335–340.

16. Shimizu K, Aikawa M, Takayama K et al. Direct Anti-Inflamatory Mechanisms Contribute to Attenuation of Experimental Allograft Arteriosclerosis by Statins. Circulation 2003; 108: 2113–2120.

17. Vítovec J, Špinarová J. Jaký statin po srdeční transplantaci? Farmakologický předpoklad a klinická praxe. Cor Vasa 2004; 46: 463–464.

18. Wu AH, Ballantyne CM, Short BC et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. Amer J Cardiol 2005; 93: 367–372.

19. Pasternak RC, Smith SC jr, Bairey-Merz CN et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024–1028.

20. Widimský J. Poškození svalů při léčbě inhibitory HMG CoA reduktázy statiny. Cor Vasa 2003; 45: 376–386.

21. Špinarová L,Toman J. Fluvastatin u pacientů po transplantaci srdce. Vnitř Lék 1998; 44: 13–16.

22. Keogh A, Macdonald P, Kaan A et al. Efficacy and Safety of Pravastatin vs Simvastatin After Cardiac Transplantation J Heart Lung Transplant 2000; 19: 529–537.

23. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–627.

24. Kobashigawa JA, Moriguchi JD, Cogert G et al. 10-year results of the pravastatin randomized trial in heart transplant recipients. ISHLT April 21–24, 2004 San Francisco, USA. Abstr. 218.

25. Bilchick KC, Henrikson CA, Skojec D et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148: 200–210.